Skip to content
← Holders

Propel Bio Management, LLC

What Propel Bio Management, LLC reported holding on Form 13F for the quarter ended Sep 30, 2026.

CIK 1969764 · Filed Nov 13, 2026

Positions
30
Reported value
$188.6M
Opened
6
Closed
5
Other managers included
1

Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR

Quarters on file

  1. Sep 30, 2025$99.9M
    16 positions
  2. Dec 31, 2025$117.1M
    20 positions
  3. Mar 31, 2026$158.7M
    38 positions
  4. Jun 30, 2026$191.1M
    29 positions
  5. Sep 30, 2026$188.6M
    30 positions
SecuritySharesChangeValueOf portfolio
PAGPPlains GP Holdings LP
1.3M±0%$33M17.5%
ACHVAchieve Life Sciences, Inc.
3.9M−4.2%$31.3M16.6%
DCTHDelcath Systems, Inc.
604.7K−30.6%$9.7M5.1%
COLLCollegium Pharmaceutical, Inc
410.2KNew$9M4.7%
CORTCorcept Therapeutics Inc
75.3K−44.9%$8.7M4.6%
AQSTAquestive Therapeutics, Inc.
278.7K−80.7%$8.6M4.6%
MISTMilestone Pharmaceuticals Inc.
9.4M+27.2%$8.2M4.3%
PHATPhathom Pharmaceuticals, Inc.
1.1M+5.3%$8.1M4.3%
CMPSCOMPASS Pathways plc
549.2KNew$6.8M3.6%
OBIOOrchestra BioMed Holdings, Inc.
896.7K±0%$5.6M3%
MAZEMaze Therapeutics, Inc.
192K+338.4%$5.2M2.8%
ABEOAbeona Therapeutics Inc.
956K−2.8%$5M2.7%
ARTVArtiva Biotherapeutics, Inc.
696.4K±0%$5M2.6%
KYTXKyverna Therapeutics, Inc.
700.6K−20.7%$4.8M2.5%
IVAInventiva S.A.
1.1M−11.5%$4.2M2.2%
CABACabaletta Bio, Inc.
2MNew$3.9M2.1%
SABSSAB Biotherapeutics, Inc.
1.2M+10.3%$3.8M2%
PROKProkidney Corp.
2MNew$3.3M1.8%
CRVSCorvus Pharmaceuticals, Inc.
264.3K+275.5%$3M1.6%
PALIPalisade Bio, Inc.
2.2M−13.9%$3M1.6%
OCULOcular Therapeutix, Inc
358K±0%$2.7M1.5%
SCYXScynexis Inc
541.5K−0.4%$2.7M1.4%
FDMT4D Molecular Therapeutics, Inc.
179.2K−29.1%$2.6M1.4%
OVIDOvid Therapeutics Inc.
1M−8.7%$2.5M1.3%
IMUXImmunic, Inc.
236.7K−27.2%$2.2M1.2%
UPBUpstream Bio, Inc.
335.4K−4.3%$1.8M0.9%
IRDOpus Genetics, Inc.
270KNew$1.3M0.7%
CLDXCelldex Therapeutics, Inc.
37.5K−63.8%$1.2M0.6%
SGPSpyGlass Pharma, Inc.
41.4KNew$1.1M0.6%
LONALeonaBio, Inc.
149.3K±0%$532.9K0.3%